Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Lu, Shun ^a,g   Pardini, Barbara ^b   Cheng, Bowang ^a   Naccarati, Alessio ^b,c   Huhn, Stefanie ^a   Vymetalkova, Veronika ^c,d   Vodickova, Ludmila ^c,d   Buchler, Thomas ^e   Hemminki, Kari ^a,f   Vodicka, Pavel ^c,d   Försti, Asta ^a,f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Human Genetics Foundation   (Italy)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Thomayer Hospital   (Czech Republic)

^f LUND UNIVERSITY   (Sweden)

^g THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; CZECH REPUBLIC; EVENT FREE SURVIVAL; FEMALE; GENDER; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; IFN GENE; IFNA1 GENE; IFNA13 GENE; IFNA14 GENE; IFNA16 GENE; IFNA17 GENE; IFNA2 GENE; IFNA21 GENE; IFNA4 GENE; IFNA5 GENE; IFNA7 GENE; IFNA8 GENE; IFNAR1 GENE; IFNAR2 GENE; IFNB1 GENE; IFNGR1 GENE; IFNGR2 GENE; IFNK GENE; IFNW1 GENE; IRF3 GENE; IRF5 GENE; IRF7 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOGENESIS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; HOSPITAL; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOSPITALS; HUMANS; INTERFERONS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84908567588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111061     Document Type: Article

References (45)

1. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, et al. (2009) The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 125: 171-180.
2. de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4: 769-780.
3. Hemminki K, Forsti A, Lorenzo Bermejo J (2009) Surveying the genomic landscape of colorectal cancer. Am J Gastroenterol 104: 789-790.
4. Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, et al. (2014) Identification of susceptibility loci for colorectal cancer in a genome-wide metaanalysis. Hum Mol Genet 23: 4729-4737.
5. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, et al. (2013) Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology 144: 799-807 e724.
6. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, et al. (2012) Metaanalysis of new genome-wide association studies of colorectal cancer risk. Hum Genet 131: 217-234.
7. Garrity-Park MM, Loftus EV, Jr., Bryant SC, Sandborn WJ, Smyrk TC (2008) Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 103: 407-415.
8. Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, et al. (2011) TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 47: 1203-1210.
9. Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, et al. (2008) Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29: 1202-1206.
10. Lu S, Bevier M, Huhn S, Sainz J, Lascorz J, et al. (2013) Genetic variants in Ctype lectin genes are associated with colorectal cancer susceptibility and clinical outcome. Int J Cancer 133: 2325-2333.
11. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375-386.
12. Savitsky D, Tamura T, Yanai H, Taniguchi T (2010) Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 59: 489-510.
13. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523.
14. Zufferey C, Erhart D, Saurer L, Mueller C (2009) Production of interferongamma by activated T-cell receptor-alphabeta CD8alphabeta intestinal intraepithelial lymphocytes is required and sufficient for disruption of the intestinal barrier integrity. Immunology 128: 351-359.
15. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, et al. (2006) IFN-gammainduced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 131: 1153-1163.
16. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK (2011) Interferonsignaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32: 1660-1667.
17. Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, et al. (2009) Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol 160: 933-940.
18. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116: 1453-1456.
19. Pardini B, Kumar R, Naccarati A, Prasad RB, Forsti A, et al. (2011) MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic. Mutat Res 721: 74-80.
20. Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, et al. (2007) An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 16: 3008-3016.
21. Burghel GJ, Lin WY, Whitehouse H, Brock I, Hammond D, et al. (2013) Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer. PLoS One 8: e83859.
22. Nelis M, Esko T, Magi R, Zimprich F, Zimprich A, et al. (2009) Genetic structure of Europeans: a view from the North-East. PLoS One 4: e5472.
23. Agesen TH, Berg M, Clancy T, Thiis-Evensen E, Cekaite L, et al. (2011) CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes Immun 12: 653-662.
24. Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74: 765-769.
25. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, et al. (2011) IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12: 231-238.
26. Esteban-Jurado C, Garre P, Vila M, Lozano JJ, Pristoupilova A, et al. (2014) New genes emerging for colorectal cancer predisposition. World J Gastroenterol 20: 1961-1971.
27. Yang JL, Qu XJ, Russell PJ, Goldstein D (2005) Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. Oncology 69: 224-238.
28. Yang JL, Qu XJ, Russell PJ, Goldstein D (2005) Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Lett 225: 61-74.
29. Wong KK, Tsang YT, Shen J, Cheng RS, Chang YM, et al. (2004) Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 32: e69.
30. Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, et al. (2004) Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res 32: e71.
31. Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 95: 221-227.
32. Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, et al. (2005) IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 163: 165-171.
33. Zhou C, Yu Q, Chen L, Wang J, Zheng S, et al. (2012) A miR-1231 binding site polymorphism in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene 507: 95-98.
34. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, et al. (2014) New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet.
35. Chen C, Guo L, Shi M, Hu M, Yu M, et al. (2012) Modulation of IFN-gamma receptor 1 expression by AP-2alpha influences IFN-gamma sensitivity of cancer cells. Am J Pathol 180: 661-671.
36. Wang Y, Liu D, Chen P, Koeffler HP, Tong X, et al. (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 68: 1136-1143.
37. Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, et al. (2007) Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13: 4139-4145.
38. Canedo P, Corso G, Pereira F, Lunet N, Suriano G, et al. (2008) The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut 57: 1504-1508.
39. Zhou J, Chen DQ, Poon VK, Zeng Y, Ng F, et al. (2009) A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. Immunogenetics 61: 423-430.
40. Koch O, Awomoyi A, Usen S, Jallow M, Richardson A, et al. (2002) IFNGR1 gene promoter polymorphisms and susceptibility to cerebral malaria. J Infect Dis 185: 1684-1687.
41. Juliger S, Bongartz M, Luty AJ, Kremsner PG, Kun JF (2003) Functional analysis of a promoter variant of the gene encoding the interferon-gamma receptor chain I. Immunogenetics 54: 675-680.
42. Rosenzweig SD, Schaffer AA, Ding L, Sullivan R, Enyedi B, et al. (2004) Interferon-gamma receptor 1 promoter polymorphisms: population distribution and functional implications. Clin Immunol 112: 113-119.
43. Donigan KA, Sun KW, Nemec AA, Murphy DL, Cong X, et al. (2012) Human POLB gene is mutated in high percentage of colorectal tumors. J Biol Chem 287: 23830-23839.
44. Iwatsuki M, Mimori K, Yokobori T, Tanaka F, Tahara K, et al. (2009) A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. J Surg Oncol 100: 261-266.
45. Hiroishi K, Tuting T, Lotze MT (2000) IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164: 567-572.